Coherus BioSciences Inc.

NASDAQ: CHRS · Real-Time Price · USD
1.05
0.03 (2.94%)
At close: Aug 15, 2025, 12:45 PM

Coherus BioSciences Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Revenue
266.96M 257.24M 211.04M 326.55M
Cost of Revenue
117.55M 158.99M 70.08M 57.59M
Gross Profit
149.41M 98.25M 140.96M 268.96M
Operating Income
-111.67M -203.2M -256.88M -263.86M
Interest Income
n/a n/a n/a n/a
Pretax Income
28.51M -238.27M -291.75M -287.1M
Net Income
28.51M -237.89M -291.75M -287.1M
Selling & General & Admin
167.74M 185.62M 198.48M 169.71M
Research & Development
93.34M 109.44M 199.36M 363.11M
Other Expenses
n/a 6.4M n/a n/a
Operating Expenses
261.07M 301.45M 397.84M 532.82M
Interest Expense
27.16M 40.54M 32.47M 22.96M
Selling & Marketing Expenses
10.9M 10.9M 10.5M 8.7M
Cost & Expenses
378.63M 460.44M 467.92M 590.41M
Income Tax Expense
n/a -380K 34.87M 19.22M
Shares Outstanding (Basic)
114.55M 94.16M 77.63M 75.45M
Shares Outstanding (Diluted)
114.83M 94.16M 77.63M 75.45M
EPS (Basic)
0.25 -2.53 -3.76 -3.81
EPS (Diluted)
0.25 -2.53 -3.76 -3.81
EBITDA
60.94M -193.94M -255.58M -260.69M
EBIT
55.66M -197.73M -259.28M -264.14M
Depreciation & Amortization
5.28M 3.79M 3.7M 3.45M